Insulin glargine 300 U/ml for the treatment of feline diabetes mellitus
| Autor: | Lucia Giacomelli, Chen Gilor, Linda M. Fleeman, Federico Fracassi, Guido Linari |
|---|---|
| Přispěvatelé: | Linari G., Fleeman L., Gilor C., Giacomelli L., Fracassi F. |
| Rok vydání: | 2021 |
| Předmět: |
Blood Glucose
medicine.medical_specialty 040301 veterinary sciences Insulin Glargine 030209 endocrinology & metabolism Cat Diseases Gastroenterology 0403 veterinary science 03 medical and health sciences chemistry.chemical_compound remission 0302 clinical medicine blood glucose curve Internal medicine Diabetes mellitus Diabetes Mellitus Animals Hypoglycemic Agents Insulin Medicine Prospective Studies Small Animals therapy fructosamine CATS business.industry Insulin glargine 04 agricultural and veterinary sciences medicine.disease Glucose Fructosamine chemistry Cats business medicine.drug |
| Zdroj: | Journal of Feline Medicine and Surgery. 24:168-176 |
| ISSN: | 1532-2750 1098-612X |
| Popis: | Objectives The study aimed to evaluate the efficacy and safety of insulin glargine 300 U/ml (IGla-U300) in cats with variable duration of diabetes mellitus (DM). Methods Thirteen client-owned cats with DM completed a prospective clinical trial. Four cats were highly suspected of hypersomatotropism and excluded from the insulin efficacy evaluation. All cats were treated with IGla-U300 SC at a starting dosage of 0.5 U/kg q12h and fed with a low carbohydrate diet. Cats were monitored for 8 weeks with a once-weekly at-home 16 h blood glucose curve (BGC) and a questionnaire evaluating the presence of DM-related clinical signs. In-clinic evaluations, including serum fructosamine measurement, were scheduled within 3 days of the first, third, sixth and eighth BGC. Glycemic variability was assessed by calculating the SD of each BGC. Results Excluding four cats suspected of hypersomatotropism, at the time of the eighth BGC, improved or absent polyuria, polydipsia, polyphagia, weight loss, lethargy and improved or normal general demeanor were reported in 8/9 (88%), 8/9 (88%), 7/9 (77%), 7/9 (77%), 7/9 (77%) and 8/9 (88%) cats, respectively. Two cats achieved remission after 29 and 53 days. Another two cats went into remission after the end of the study (days 82 and 96). All cats that achieved remission were newly diagnosed diabetics. Median (range) serum fructosamine concentration significantly decreased when comparing the time of enrollment (604 [457–683] µmol/l) with the eighth week of treatment (366 [220–738] µmol/l) ( P = 0.02). In all 13 cats, biochemical hypoglycemia (blood glucose Conclusions and relevance IGla-U300 seems effective and safe for the treatment of feline diabetes, but more long- term and comparative clinical trials are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|